We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of migraine in adult patients who experience at least four migraine days per month.
With the approval, Ajovy becomes the first and the only anti-CGRP treatment to secure a nod in the EU with monthly and quarterly dosing options for patients to follow.
The approval was expected as in February, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion, recommending approval of Ajovy
This generic drugmaker’s shares have risen 1.9% this year so far compared with the industry’s increase of 9.6%.
Ajovy (fremanezumab), for prevention of chronic/episodic migraine, was approved by the FDA in September last year. Regarding its launch uptake in the United States, Teva said, on the fourth-quarter conference call in February, that Ajovy has been performing strongly, enjoying growing demand due to its flexible dosing options - quarterly and monthly. Teva said that Ajovy has captured around 30% of new to brand patients. Ajovy recorded sales of $3 million in 2018. On the call, the company guided sales of approximately $150 million in the United States in 2019. With the approval in Europe, sales of Ajovy should be higher.
However, Ajovy faces intense competition from Amgen (AMGN - Free Report) /Novartis (NVS - Free Report) and Lilly’s (LLY - Free Report) CGRPs, Aimovig and Emgality, respectively. Both were also approved by the FDA in mid-2018. Both are also approved in EU.
Fremanezumab is also being evaluated in a late-stage study for episodic cluster headache and in a mid-stage study for post traumatic headache. Teva is optimistic that Ajovy could emerge as significant contributor to its long-term sales growth.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of migraine in adult patients who experience at least four migraine days per month.
With the approval, Ajovy becomes the first and the only anti-CGRP treatment to secure a nod in the EU with monthly and quarterly dosing options for patients to follow.
The approval was expected as in February, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion, recommending approval of Ajovy
This generic drugmaker’s shares have risen 1.9% this year so far compared with the industry’s increase of 9.6%.
Ajovy (fremanezumab), for prevention of chronic/episodic migraine, was approved by the FDA in September last year. Regarding its launch uptake in the United States, Teva said, on the fourth-quarter conference call in February, that Ajovy has been performing strongly, enjoying growing demand due to its flexible dosing options - quarterly and monthly. Teva said that Ajovy has captured around 30% of new to brand patients. Ajovy recorded sales of $3 million in 2018. On the call, the company guided sales of approximately $150 million in the United States in 2019. With the approval in Europe, sales of Ajovy should be higher.
However, Ajovy faces intense competition from Amgen (AMGN - Free Report) /Novartis (NVS - Free Report) and Lilly’s (LLY - Free Report) CGRPs, Aimovig and Emgality, respectively. Both were also approved by the FDA in mid-2018. Both are also approved in EU.
Fremanezumab is also being evaluated in a late-stage study for episodic cluster headache and in a mid-stage study for post traumatic headache. Teva is optimistic that Ajovy could emerge as significant contributor to its long-term sales growth.
Teva currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>